Glioblastoma targeted therapy: updated approaches from recent biological insights

by Touat, M., Idbaih, A., Sanson, M., Ligon, K. L.
Published in Ann Oncol (2017)

P04.10 Chains of magnetosomes induce full destruction of intracranial U87-Luc and subcutaneous GL-261 glioma in mice under the application of an alternating magnetic field

by Alphandery, E, Idbaih, A, Adam, C, Delattre, J, Schmitt, C, Guyot, F, Chebbi, I
Published in Neuro Oncol (2018)

P04.14 IDH1 MUTATION IN LOW-GRADE GLIOMAS RELATED TO EPILEPSY AS INITIAL SYMPTOM

by Duran-Peña, A., Mokhtari, K., Marie, Y., Alentorn, A., Delattre, J., Idbaih, A., Sanson, M., Vecht, C.
Published 2014

P17.08 RENAL THROMBOTIC MICROANGIOPATHY INDUCED BY BEVACIZUMAB IN HIGH GRADE GLIOMA PATIENTS - ABOUT SIX CASES

by Blonski, M., Simon, L., Houillier, C., Idbaih, A., Wittwer, B., Beauchesne, P., Hoang-Xuan, K., Taillandier, L.
Published 2014

P10.14 Long-term impact of Temozolomide on 1p19q codeleted oligodendrogliomas growth kinetics

by Izquierdo, C., Alentorn, A., Simó, M., Idbaih, A., Ricard, D., Kaloshi, G., Bruna, J., Honnorat, J., Delattre, J., Ducray, F.
Published in Neuro Oncol (2017)

OS5.5 Characteristics of high-grade gliomas with H3 G34 mutation in adults

by Picart, T, Barritault, M, Tabouret, E, Idbaih, A, Izquierdo Gracia, C, Poncet, D, Honnorat, J, Meyronet, D, Guyotat, J, Ducray, F
Published in Neuro Oncol (2019)

P05.05 Safety and feasibility of temporary blood-brain barrier disruption with the SonoCloud-1/3 implantable ultrasound device in recurrent glioblastoma

by Idbaih, A, Canney, M, Bouchoux, G, Desseaux, C, Vignot, A, Lafon, C, Chapelon, J, Delattre, J, Belin, L, Carpentier, A
Published in Neuro Oncol (2019)

OS11.3 Machine learning for better prognostic stratification and driver genes identification in 1p/19q-codeleted grade III gliomas

by Rosenberg, S., Dehais, C., Ducray, F., Alentron, A., Tanguy, M., De Reyneis, A., Elarouci, N., Figarella-Branger, D., Delattre, J., Idbaih, A.
Published in Neuro Oncol (2017)

EH1.3 EORTC 26101 phase III trial exploring the combination of bevacizumab and lomustine versus lomustine in patients with first progression of a glioblastoma

by van den Bent, M., Gorlia, T., Bendszus, M., Sahm, F., Domont, J., Idbaih, A., Platten, M., Weller, M., Golfoinopoulos, V., Wick, W.
Published in Neuro Oncol (2016)

P01.148 Intra-tumor heterogeneity analysis of low-grade gliomas. A POLA Network study

by Alentorn, A, Labreche, K, Dehais, C, Carpentier, C, Ducray, F, Mokhtari, K, Figarella-Branger, D, Sanson, M, Delattre, J, Idbaih, A
Published in Neuro Oncol (2018)

P06.18 DNA methylation distance score in lower-grade gliomas has prognostic value: a POLA network study

by Alentorn, A., Kamoun, A., Ducray, F., Dehais, C., Mokhtari, K., Uro-Coste, E., Figarella-Branger, D., Delattre, J., Idbaih, A., Sanson, M.
Published in Neuro Oncol (2016)

P06.19 TERT promoter mutation is an independent prognostic factor in 1p/19q co-deleted oligodendrogliomas: a POLA network study

by Alentorn, A., Carpentier, C., Labreche, K., Ducray, F., Dehais, C., Mokhtari, K., Uro-Coste, E., Figarella-Branger, D., Delattre, J., Idbaih, A.
Published in Neuro Oncol (2016)

O10.02 MITOTIC INDEX, MICROVASCULAR PROLIFERATION AND NECROSIS DEFINE THREE GROUPS OF 1P/19Q CO-DELETED ANAPLASTIC OLIGODENDROGLIOMAS ASSOCIATED WITH DIFFERENT GENOMIC ALTERATIONS

by Figarella-Branger, D., Mokhtari, K., Dehais, C., Jouvet, A., Uro-Coste, E., Colin, C., Carpentier, C., Ducray, F., Idbaih, A., Network, French POLA
Published 2014

P20.01 MEVITEM: A European, randomized, open-label Phase I/II study of vismodegib in combination with temozolomide versus temozolomide alone in adult patients with recurrent or ref...

by Frappaz, D., Meyronnet, D., Garin, G., Laigle-Donadey, F., Le Rhun, E., Bonneville-Levard, A., Frenel, J., Idbaih, A., Gourmelon, C., Chinot, O.
Published in Neuro Oncol (2016)

P09.14 Clonal and subclonal evolution of 1p/19q co-deleted oligodendrogliomas

by Alentorn, A., Daniau, M., Royer-Perron, L., Labreche, K., Duran-Pena, A., Marie, Y., Hoang-Xuan, K., Sanson, M., Delattre, J., Idbaih, A.
Published in Neuro Oncol (2016)

P11.59 Integrin a5 heterogeneous expression in glioblastoma is related to glioma stem cell subpopulations

by Dontenwill, M, Mercier, M, Gillmann, G, Reita, D, Lelong-Rebel, I, Noulet, F, Idbaih, A, Herold-Mende, C, Bagnard, D, Spenlé, C, Martin, S
Published in Neuro Oncol (2019)

OS8.5 How to assess meningioma therapy activity: The CEVOREM independent central review experience

by GRAILLON, T, Colin, T, Peyrière, H, Peyre, M, Tabouret, E, Campello, C, Idbaih, A, Boucekine, M, Figarella-Branger, D, Kalamarides, M, Dufour, H, Sanson, M, Chinot, O
Published in Neuro Oncol (2019)

P17.01 CHROMOSOME ARM 9P LOSS OF HETEROZYGOSITY IS A MARKER OF SHORTER SURVIVAL IN 1P/19Q CO-DELETED ANAPLASTIC OLIGODENDROGLIOMA. A POLA NETWORK STUDY

by Alentorn, A., Dehais, C., Carpentier, C., Mokhtari, K., Ducray, F., Figarella-Branger, D., Delattre, J., Idbaih, A., (POLA)”, POLA Network “Prise en charge des OLigodendrogliomes Anaplasiques
Published 2014

OS5.2 Health-Related Quality of Life (HRQoL) in patients with progressive glioblastoma treated with combined bevacizumab and lomustine versus lomustine only (randomized phase III E...

by Taphoorn, M. J. B., Bottomley, A., Coens, C., Reijneveld, J. C., Gorlia, T., Brandes, A. A., Domont, J., Idbaih, A., van den Bent, M. J., Wick, W.
Published in Neuro Oncol (2016)

OS5.7 First results of the randomized phase II TAVAREC trial on temozolomide with or without bevacizumab in 1p/19q intact 1st recurrence grade II and III glioma

by Idbaih, A., Clement, P. M., Vos, F. Y. F., Platten, M., Mulholland, P., Taphoorn, M. J. B., Lewis, L., Golfinopoulos, V., Gorlia, T., van den Bent, M. J.
Published in Neuro Oncol (2016)